News & Updates

Lecanemab reduces brain amyloid burden and offers moderate slowing of cognitive decline in early Alzheimer’s disease (AD), but is associated with adverse events (AEs), according to the results of the phase III, double-blind, placebo-controlled CLARITY AD trial, presented at the 15^th Clinical Trials on Alzheimer’s Disease (CTAD 2022) conference.

Researchers from the University of Hong Kong (HKU) report that the incidence of “young stroke” (ie, strokes occurring in those aged 18–55 years) has increased by 30 percent in Hong Kong’s residents since 2001.

Among adults with autism spectrum disorder (ASD), group-based cognitive behavioural therapy (CBT) appears to yield modest improvements in emotion regulation, a recent study has found.

Users of attention-deficit/hyperactivity disorder (ADHD) medications across age groups do not appear to be at increased risk of cardiovascular diseases (CVDs), although a modest risk increase of cardiac arrest or tachyarrhythmias could not be ruled out, according to the results of a meta-analysis.

Oral ENT-01 safely and significantly improves constipation in patients with Parkinson’s disease (PD), results of a phase IIb study have shown.

Tongxinluo, added to guideline-directed therapy, improves outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI) in the large, multicentre CTS-AMI* study. But experts are clamouring for more evidence of efficacy.

In advanced dementia patients with feeding problems, careful hand feeding (CHF) is associated with a 40 percent lower risk of pneumonia and similar 1-year survival rate vs nasogastric tube feeding (NGF), a retrospective cohort study in Hong Kong has shown.

Using collateral flow findings, as seen on computed tomographic (CT) angiography, may widen the population who can undergo late endovascular treatment (EVT) for acute ischaemic stroke (AIS), according to findings of the MR CLEAN-LATE trial.